drugset / Trial / NCT01822041

14C-ARN-509 Microtracer Label AME and Absolute BA Study

NCT01822041

Phase 1 Completed 12 enrolled Aragon Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is study in healthy human volunteers to determine the absorption, metabolism, and excretion (AME) profile of ARN-509 as well as its absolute oral bioavailability (BA).

Timeline

Start
2013-03
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Apalutamide Small molecule 100 ug Oral
Comparator Apalutamide Small molecule 240 mg Oral

Indications

No indication recorded.